Nandron50 mg/ml

Nandron is an injectable anabolic-androgenic steroid used for specific, physician-supervised medical indications. It is not indicated for physique or athletic performance enhancement, and such non-medical use is inappropriate and potentially dangerous.

• Anemia of renal insufficiency: An established use of Nandron is to stimulate erythropoiesis (red blood cell production) in the anemia associated with chronic renal failure. This use has been largely superseded by erythropoiesis-stimulating agents (e.g., erythropoietin) in modern practice, but Nandron may still be used as an adjunct or alternative in select patients.
• Aplastic anemia and other refractory anemias: Nandron may be used as an adjunct to supportive care (transfusions, corticosteroids) in aplastic anemia and other bone-marrow-failure anemias, generally when other measures are inadequate.
• Established osteoporosis: In some markets, Nandron is used to help increase bone mass and reduce fracture risk in established osteoporosis, particularly in postmenopausal women, usually alongside calcium, vitamin D, and other standard osteoporosis therapy.
• Catabolic and protein-deficiency states: Nandron is used in some settings to promote protein anabolism and improve nitrogen balance in patients with chronic debilitating disease, malnutrition, or post-surgical catabolic states, as an adjunct to adequate diet.
• Palliative therapy in disseminated breast cancer (women): In some markets, Nandron is used as palliative, hormonal adjunct therapy in selected women with advanced, disseminated breast cancer.

Use of Nandron for bodybuilding, athletic enhancement, or cosmetic muscle gain is an off-label, non-medical use that is not supported by regulatory approval and carries substantial health risks; it is discouraged and, in many jurisdictions, illegal without a prescription.

Each ampoule/vial contains Nandrolone Decanoate as the active ingredient, formulated as a sterile oily solution for intramuscular injection, typically 25 mg/mL or 50 mg/mL, in a vegetable (e.g., arachis/peanut or sesame) oil base with benzyl alcohol or benzyl benzoate as excipients.

Nandron is a synthetic anabolic-androgenic steroid, a derivative of testosterone (19-nortestosterone) esterified with decanoic acid to prolong its duration of action. It is formulated as an oily intramuscular injection and is classified as a controlled substance in many countries due to its potential for misuse.

Medically, Nandron exerts anabolic (tissue-building) and androgenic (masculinizing) effects, and is used under close physician supervision for select indications such as certain anemias, osteoporosis, and catabolic states. Its use outside legitimate medical supervision, including for physique or performance enhancement, is not approved and carries significant risk.

Nandron belongs to the therapeutic class of anabolic-androgenic steroids (AAS), a subgroup of sex hormones and modulators of the genital system. It is a synthetic derivative of testosterone with a favorable anabolic-to-androgenic activity ratio compared to testosterone itself.

Nandrolone Decanoate is the decanoate ester of nandrolone (19-nortestosterone), a synthetic androgen. After intramuscular injection, the ester is slowly hydrolyzed to release free nandrolone, which binds to androgen receptors in target tissues (muscle, bone, bone marrow, and others), producing anabolic (protein-synthesis-promoting, nitrogen-retaining) effects along with weaker androgenic (masculinizing) effects than testosterone.

Key pharmacological actions of Nandrolone Decanoate include: stimulation of erythropoiesis (partly via increased erythropoietin production and direct bone marrow stimulation), increased bone mineral density through effects on osteoblast activity, and promotion of positive nitrogen balance and protein anabolism. The decanoate ester confers a prolonged duration of action, with a single intramuscular dose providing effects for approximately 1-3 weeks, which is why dosing intervals are typically every 1-4 weeks.

Nandrolone Decanoate also suppresses the hypothalamic-pituitary-gonadal axis (reducing endogenous gonadotropin and testosterone production) and can alter lipid profiles (increasing LDL and decreasing HDL cholesterol) and fluid/electrolyte balance (sodium and water retention).

Nandron must be administered only by deep intramuscular injection (typically into the gluteal muscle) by a trained healthcare professional. It must never be given intravenously. The oily injection should be given slowly, and injection sites should be rotated to reduce local irritation. Do not self-inject or share this medicine, needles, or syringes with others.

Nandron has several clinically significant drug interactions that require monitoring or dose adjustment:

• Oral anticoagulants (e.g., warfarin): Anabolic steroids including Nandron can potentiate the anticoagulant effect, increasing bleeding risk. Coagulation parameters (INR/prothrombin time) should be monitored closely and anticoagulant dose adjusted as needed.
• Insulin and oral antidiabetic agents: Nandron can improve glucose tolerance and decrease insulin or antidiabetic drug requirements; blood glucose should be monitored and doses adjusted to avoid hypoglycemia.
• Corticosteroids and ACTH: Concurrent use with Nandron may increase the risk of fluid retention and edema; caution is advised, particularly in patients with cardiac or hepatic disease.
• Hepatotoxic drugs: Concurrent use of other potentially hepatotoxic medications with Nandron may increase the risk of liver injury; liver function should be monitored.

Adverse effects of Nandron are generally dose- and duration-related and more prominent with prolonged or high-dose use.

• Endocrine/reproductive: In women - virilization (deepening of voice, hirsutism, clitoral enlargement, acne, menstrual irregularities), which may be irreversible with continued use. In men - suppression of endogenous testosterone, testicular atrophy, reduced sperm count, gynecomastia, and priapism.
• Hepatic: Elevated liver enzymes, cholestatic jaundice, and, with prolonged use, rare but serious peliosis hepatis and hepatocellular tumors (including hepatocellular carcinoma).
• Cardiovascular/metabolic: Adverse changes in lipid profile (decreased HDL, increased LDL cholesterol), fluid and sodium retention, edema, and increased cardiovascular risk with long-term use.
• Skin: Acne, oily skin, hirsutism.
• Other: Insomnia, mood changes, increased or decreased libido, hypercalcemia (particularly in breast cancer patients), and injection-site pain or irritation.

Pregnancy: Nandron is contraindicated in pregnancy because androgens can cause varying degrees of virilization in the female fetus (e.g., clitoral enlargement, abnormal vaginal development, voice changes). It must not be used by pregnant women or women who may become pregnant.

Lactation: It is not known whether Nandron or its metabolites pass into human breast milk. Because androgens can potentially affect infant growth and development, breastfeeding is not recommended during treatment with Nandron; a physician should be consulted to weigh the need for therapy against infant feeding options.

Nandron should be used only under close physician supervision, with the following precautions:

• Hepatic effects: Long-term use has been associated with peliosis hepatis and hepatic tumors (see Side Effects); periodic liver function monitoring is advised, and therapy should be discontinued if abnormal liver function or jaundice develops.
• Cardiovascular risk: May adversely affect serum lipids and cause fluid retention; use with caution in patients with cardiac, renal, or hepatic disease, or hypertension, due to risk of edema and worsened heart failure.
• Virilization: Female patients should be monitored for signs of virilization; some effects (e.g., voice changes) may not be reversible if therapy is continued after they appear. Therapy should be stopped promptly if mild virilization is noted.
• Prostate monitoring: In older men, Nandron may accelerate subclinical prostate cancer or cause prostatic hyperplasia; periodic prostate monitoring is recommended.
• Growth in children: Can accelerate bone maturation without a proportional increase in linear growth, risking premature epiphyseal closure and compromised adult height; bone age should be monitored regularly in pediatric patients (see Use in Special Populations).
• Edema: May cause fluid retention; use with caution in patients predisposed to edema.
• Abuse potential: Nandron has recognized potential for misuse and dependence when used for non-medical (e.g., physique or performance enhancement) purposes; it is a controlled substance in many countries and should be used strictly as prescribed, never shared with others, and never used without medical supervision.

Specific data on acute overdose with Nandron are limited, as it is administered by injection under medical supervision. Excessive or prolonged dosing may increase the risk of the adverse effects described above, particularly virilization, hepatotoxicity, and cardiovascular/lipid effects. If an overdose or excessive dosing is suspected, seek immediate medical attention or contact a poison control center; treatment is supportive and symptomatic, and there is no specific antidote.

Store at room temperature, between 20°C and 25°C, protected from light, in the original carton. Do not freeze. Keep out of reach of children.

Pediatric use: Nandron may be used in children (approximately 2-13 years) for anemia under specialist supervision, but it can cause premature closure of bone growth plates and compromise final adult height; treatment should be as brief as possible, at the lowest effective dose, with regular monitoring of bone age (every 6 months) and growth. Safety and efficacy for other pediatric indications are not established.

Geriatric use: Older men treated with Nandron are at increased risk of prostatic hyperplasia and may have occult prostate carcinoma unmasked or accelerated; periodic prostate examination is recommended. Elderly patients may also be more susceptible to fluid retention and cardiovascular adverse effects.

Hepatic impairment: Use with caution; Nandron is associated with hepatotoxicity, and it should be avoided or used only with close monitoring in patients with significant hepatic impairment.

Renal impairment: While used in renal-disease-associated anemia, Nandron is contraindicated in nephrosis or the nephrotic phase of nephritis (see Contraindications); use with caution and monitoring in other renal impairment.

The duration of treatment with Nandron should be individualized by the treating physician based on indication and response, and reassessed periodically (e.g., every few weeks to months). Treatment is generally intended to be time-limited, particularly in children and for catabolic/anemia indications, and should not be continued longer than necessary given its cumulative risks of hepatotoxicity, virilization, and cardiovascular effects.

Anabolic-androgenic steroid (AAS); synthetic testosterone (19-nortestosterone) ester.

Nandrolone Decanoate is hydrolyzed after intramuscular injection to release free nandrolone, which binds androgen receptors to promote protein anabolism, nitrogen retention, and erythropoiesis, while exerting comparatively weaker androgenic (masculinizing) effects than testosterone; it also suppresses pituitary gonadotropin secretion via negative feedback.

X

Nandron may be used in children roughly 2-13 years of age for anemia, under specialist supervision, typically at 25-50 mg by deep intramuscular injection every 3-4 weeks. Because it can cause premature closure of the epiphyseal growth plates and compromise final adult height, treatment should be limited to the lowest effective dose for the shortest necessary duration, with bone age (wrist X-ray) monitored approximately every 6 months during therapy. Safety and efficacy of Nandron for indications other than anemia have not been established in children, and it should never be used in children for non-medical (growth or physique) purposes.